Comparison · NCT01305213-sae
Arm I Bevacizumab vs Arm II Bevacizumab + Fosbretabulin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I Bevacizumab vs Arm II Bevacizumab + Fosbretabulin: serious adverse events. Trial comparisons, record NCT01305213-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01305213-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.17 | 0.092 | 0.292 | wilson | |
| Risk in group 2 | 0.296 | 0.191 | 0.428 | wilson | |
| Risk difference, group 1 minus group 2 | -0.126 | -0.28 | 0.0348 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.573 | 0.278 | 1.18 | log | |
| Odds ratio, group 1 over group 2 | 0.486 | 0.193 | 1.22 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm I Bevacizumab than on Arm II Bevacizumab + Fosbretabulin | 7.91 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I Bevacizumab | Bevacizumab 15mg/kg IV Day 1 every 3 weeks | 9 | 53 | EG000 |
| Group 2 | Arm II Bevacizumab + Fosbretabulin | Bevacizumab 15mg/kg IV Day 1 every 3 weeks plus fosbretabulin tromethamine 60mg/m2 IV Day 1 every 3 weeks | 16 | 54 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All adverse Events (AEs) occurring during treatment and up to 30 days after stopping the study treatment are reported. Also reported are Serious Adverse Events (SAEs) considered to be treatment related for up to 5 years after stopping study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
- NCT number
- NCT01305213
- Phases
- PHASE2
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2017-07-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01305213?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01305213-sae